Country for PR: Hong Kong
Contributor: PR Newswire Asia (Hong Kong)
Wednesday, January 13 2021 - 18:44
AsiaNet
Holmusk, National Healthcare Group and Institute of Mental Health outline strategic collaboration to strengthen mental healthcare in Singapore
SINGAPORE, Jan. 13, 2021 /PRNewswire-AsiaNet/ --

Holmusk has signed a Memorandum of Understanding (MOU) with Singapore's 
National Healthcare Group (NHG) and the Institute of Mental Health (IMH), to 
jointly develop innovative solutions for mental healthcare. The MOU outlines a 
shared vision to use digital technology, data and predictive analytics to help 
improve the mental health and well-being of the population.

The tripartite partnership seeks to address the unmet clinical needs of 
patients, populations and healthcare professionals, through leveraging the 
clinical expertise and translational research capabilities of NHG and IMH, and 
Holmusk's expertise in generating insights from mental health real-world data 
through advanced analytics and digital technology. Building on its evidence 
generation platform (NeuroBlu) and digital therapeutics platform (mConnect), 
Holmusk will work closely with NHG and IMH to co-develop tools that aim to 
enable earlier detection and intervention in mental health disorders such as 
depression by using advanced analytics. They include identifying and validating 
novel digital biomarkers for mental health through the use of integrated and 
protected data from clinical records and smartphones, which can provide a more 
objective measure of an individual's mental state, as well as conditions 
including depression and schizophrenia. Holmusk, NHG and IMH will also 
co-develop a suite of digital therapeutics and tools for mental healthcare that 
can be used in hospitals and clinics across primary care and community 
settings, beginning with Major Depressive Disorder (MDD).

According to the 2016 Singapore Mental Health Study, about one in seven people 
in Singapore has experienced a mental health condition in their lifetime. 
Despite MDD being the most common mental disorder, a high proportion of people 
with mental disorders, including MDD, do not seek help, thus resulting in a 
significant treatment gap. The COVID-19 pandemic has highlighted the importance 
of mental health, with more people seeking help for mental health issues such 
as anxiety and depression.

"Holmusk is committed to bring its existing assets and deep expertise in data 
analytics and digital technology to transform mental healthcare. We believe 
that using technology to generate novel insights will transform our current 
understanding of mental health and lay the foundation for a whole new 
generation of treatments," said Nawal Roy, Founder and CEO at Holmusk. "Care 
teams will be able to identify patients with more urgent needs, allowing these 
patients to get the right support in a timely manner."

"Digital technology will change how mental health conditions are diagnosed, 
monitored, and even treated," said Professor Benjamin Seet, Deputy Group CEO 
(Education and Research) and Group Chief Research Officer at NHG. "Our 
partnership with Holmusk is game-changing. Coupled with Singapore's strong 
healthcare, IT and data infrastructure, we are well-poised to break new ground 
in this exciting space."       

"Clinicians need corroborative information from as many sources as possible in 
psychiatric assessments. Digital biomarkers will be yet another source and can 
supplement clinical expertise to help us reach an accurate diagnosis and also 
monitor our patients closely. This, together with a digital suite of care 
services, signals the potential for a more personalised treatment for 
patients," said Professor Chua Hong Choon, Chief Executive Officer, IMH.

About Holmusk

Holmusk is on a mission to transform the lives of people with behavioural 
health and chronic diseases through evidence driven medicine. Headquartered in 
Singapore with a global footprint, Holmusk develops digital solutions to 
advance health innovation, research, and care, and is building the world's 
largest real-world evidence platform for behavioural health and chronic diseases

Holmusk's analytics platform synthesizes Real-World Data (RWD) with proprietary 
disease progression models to create actionable insights for behavioural health 
research, innovation, and care delivery. Holmusk's Real-World Evidence Platform 
is powered by one of the largest longitudinal de-identified behavioural health 
databases, with data from more than 550,000+ patients collected over 20+ years 
and 20+ million visits.  Holmusk is continuously enhancing its database by 
partnering with health systems globally. In addition, Holmusk builds digital 
health solutions that enhance patient engagement, support disease 
self-management, and capture patient-reported outcomes to guide clinical 
decisions and analytics. For more information, please visit www.holmusk.com

About National Healthcare Group

The National Healthcare Group (NHG) is a leader in public healthcare in 
Singapore, recognised at home and abroad for the quality of its medical 
expertise and facilities. Care is provided through an integrated network of six 
primary care polyclinics, acute care and tertiary hospitals, national specialty 
centres and business divisions. Together they bring a rich legacy of medical 
expertise to our philosophy of integrated patient-centred care.

NHG's vision is "Adding Years of Healthy Life". This vision goes beyond merely 
healing the sick to the more difficult and infinitely more rewarding task of 
preventing illness and preserving health and quality of life. With some 20,000 
staff, NHG aims to provide care that is patient-centric, accessible, seamless, 
comprehensive, appropriate and cost-effective.

As the Regional Health System (RHS) for Central Singapore, it is vital for NHG 
to partner and collaborate with stakeholders, community advisors, and voluntary 
welfare organisations. Together with our patients, their families and 
caregivers, we aim to deliver integrated healthcare services and programmes 
that help in Adding Years of Healthy Life to all concerned.

More information is available at www.nhg.com.sg.

About Institute of Mental Health

The Institute of Mental Health (IMH), a member of the National Healthcare 
Group, is the only tertiary psychiatric care institution in Singapore. Located 
on the sprawling 23-hectare campus, IMH offers a multidisciplinary and 
comprehensive range of psychiatric, rehabilitative and therapy services in 
hospital-based and community-based settings. The 2010-bedded hospital aims to 
meet the needs of three groups of patients - children and adolescents (aged 
below 19 years), adults and the elderly. Besides providing clinical services, 
IMH also leads in mental health research and training the next generation of 
mental health professionals in Singapore. For more information, please visit 
www.imh.com.sg.

SOURCE Holmusk

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=382074

   Caption: Holmusk, National Healthcare Group and Institute of Mental Health

Attachments
Holmusk.jpg